



Comisión Nacional del Mercado de Valores
Att. Director del Área de Mercados
c/ Edison núm. 4
28006 Madrid

Madrid, 28 de febrero de 2025

De conformidad con lo previsto en el artículo 227 de la Ley 6/2023, de 17 de marzo, de los Mercados de Valores y de los Servicios de Inversión, y disposiciones concordantes, ponemos en su conocimiento la siguiente

OTRA INFORMACIÓN RELEVANTE

La Sociedad remite la presentación que se expondrá en la teleconferencia organizada con analistas e inversores relativa a los resultados correspondientes al ejercicio 2024, que se celebrará hoy, viernes 28 de febrero de 2025, a las 13:30 (CET).


Para unirse a la teleconferencia, se recomienda registrarse en [este enlace](#) para recibir los números de acceso y un PIN personalizado.

Para acceder sin registro previo, utilizar los siguientes números: +34 919 01 16 44 (España), +1 646 233 4753 (EE.UU.) o +44 20 3936 2999 (Reino Unido). Número de conferencia: 883194. Además, los interesados podrán seguir la presentación en directo través de [este enlace](#).



FY 2024 Results Presentation

Madrid, February 28th 2025






AGENDA

1. FINANCIAL HIGHLIGHTS
2. BUSSINES UPDATE
3. Q&A & CLOSING REMARKS



José Luis Moreno
*VP, Director Capital Markets
and Investor Relations*



AGENDA

1. FINANCIAL HIGHLIGHTS
2. BUSINESS UPDATE
3. Q&A & CLOSING REMARKS




Mª Luisa de Francia
Chief Financial Officer


Main financial figures

Revenues


Revenues evolution (€ '000)




Total revenues by product



Recurring revenues breakdown (€ '000)



2024 revenues breakdown by product (€ mn)



Key Financial Highlights

Main figures

(€ '000)	2023	2024	Var (%)
Revenues:			
Product sales	71,873	66,542	-7.4%
Licensing agreements	33,590	46,518	38.5%
Royalties	52,178	61,347	17.6%
Other	512	448	-12.5%
Total revenues	158,153	174,855	10.6%
Cost of Sales	-9,613	-8,183	-14.9%
Gross Profit	148,540	166,672	12.2%
Marketing expenses	-23,542	-22,809	-3.1%
General and administrative expenses	-18,263	-24,372	33.5%
Research and Development expenses	-99,302	-103,502	4.2%
Net impairment on financial assets	271	217	-19.9%
Other operating expenses	-12,783	-13,425	5.0%
Other results	1,252	3,687	194.5%
Operating profit	-3,827	6,468	n.a.
Net financial result	204	5,517	n.a.
Profit before tax	-3,623	11,985	n.a.
Income tax expense	4,760	14,140	n.a.
Net profit	1,137	26,125	n.a.

- **R&D increased 4%** to €103.5mn in 2024, related to the significant increase of the activity in both LAGOON and SaLuDo trials.
- **EBITDA reached €13mn** as of December 2024, compared to €2.1mn in December 2023.
- Total financial debt amounted to €47.8mn, with total cash and cash equivalents of €157mn. **Total net cash position** of €109mn as of December 2024.
- As of December 2024, the company has generated **€6.0mn in operating cash flow**, an increase of €19.5 million compared to the same period of the previous year (-€13.5mn as of December 2023).

ESG

Remarkable issues during FY24

- Publication of the **Non-Financial Information Consolidated Statement and Sustainability Report** according to CSRD and 11/2018 Spanish Law on non-financial information and diversity.
- Approval, by **the Board of Directors**, of the following issues:
 - Human Rights Policy
 - Biodiversity Policy
 - Sustainability Plan 2024-2026
- **Net Zero Plan** for the decarbonization of the company in 2050.
- **Climate Risks and Opportunities** Report.









Luis Mora
Managing Director

AGENDA

1. FINANCIAL HIGHLIGHTS
2. BUSINESS UPDATE
3. Q&A & CLOSING REMARKS

Pipeline – Expanding our Expertise in Oncology

			Phase 1	Phase 2	Phase 3	Market
	Soft tissue Sarcoma	Monotherapy	2 nd /3 rd line			
	Ovarian cancer	+ PLD (pegylated liposomal doxorubicin)	2 nd /3 rd line			
	R/R Multiple Myeloma ¹	+ dexamethasone	3 rd /4 th line			
	Small cell lung cancer	Monotherapy	2 nd line US / other countries			
	Small cell lung cancer maintenance	+ atezolizumab	1 st line maintenance			 
	Small cell lung cancer	Lurbi vs. lurbi+ irinotecan vs. topotecan or irinotecan	2 nd line		LAGOON	
	Leiomyosarcoma	+ doxorubicin	1 st line	Phase IIb/III		
	Small cell lung cancer	+ irinotecan	2 nd line			
	Small cell lung cancer combo ²	+ atezolizumab	2 nd line			
	Solid tumours (basket trial)	Monotherapy				
	Solid tumours	Combination trials with IO				
	Soft tissue sarcoma ²	Combination radiation				
PM534	Solid tumours	Monotherapy				
PM54	Solid tumours	Monotherapy				

(1) Approved in Australia
 (2) IST – Investigator Sponsored Trial

Positive results from the IMforte Phase 3 clinical trial

Statistically significant and clinically meaningful OS & PFS benefit

- The combination of lurbinectedin and atezolizumab demonstrated a **positive, statistically significant and clinically meaningful improvement** in the two primary endpoints of overall survival (OS) and progression-free survival (PFS).
- PharmaMar will submit a **marketing authorization application (MAA)** to the EMA in the first half of 2025 to obtain the approval in Europe.
- Jazz will also submit a **supplemental New Drug Application (sNDA)** to the FDA.

Lurbinectedin

European Market Opportunity

Leiomyosarcoma

- **SaLuDo trial** (Phase IIb/II)
- 1st line therapy in combination with doxorubicin
- **End of recruitment expected 1Q26**
- **Longer treatment duration**

SCLC – 2nd line


- **LAGOON trial**
- 2nd line therapy
- Two arms:
 - Monotherapy
 - Combo with irino
- Recruitment ended 4Q24
- **Nothing approved in 2L since 1996**

SCLC – 1st line maint.

- **IMforte trial.**
- Combination of lurbinectedin + atezolizumab
- Longer treatment duration
- **Potential to be practice-changing**
- **Filing 1H25**


Lurbinectedin. Pathway to market in EU

Key events



Lurbinectedin: Commercial outlook

Global presence



Clinical development

Key pillars for sustainable growth

2025

2026

2027

2028

Potential indications:

PM14
(Ecubectedina)

- Small Cell Neuroendocrine High-Grade Prostate Cancer
- Combination IO on-going

PM54

- Potential 2nd generation of lurbinectedin
- Good safety profile
- Early signs of activity in solid tumors
- Phase I/II combos & monotherapy basket trial planned


PM534

- Unique / Novel tubulin inhibitor
- No neurotoxicity
- Early signs of activity in solid tumors
- Phase I/II combos & monotherapy planned

Phase III trials

Long-term sustainable value creation for our shareholders

Driving process across our strategic pillars





AGENDA

1. OPERATIONAL UPDATE
2. FINANCIAL HIGHLIGHTS
3. Q&A & CLOSING REMARKS



Pharma
Mar

www.pharmamar.com